Introduction
Most regulatory updates arrive with a press release, a few industry blog posts, and a quiet implementation that most practitioners catch up to months later. CNIPA Order No. 84 is different.
Effective January 1, 2026, China’s National Intellectual Property Administration enacted the most comprehensive revision to the Patent Examination Guidelines in years. Twenty-three chapters revised across all five major parts of the guidelines. New examination standards for AI-related inventions. A ban on same-day dual filing of invention patents and utility models. Stricter rules against repeat invalidation filings. New inventor identity requirements. Clarified examination standards for bitstream and algorithm applications.
For international companies with Chinese patent portfolios — or companies planning to file in China — this isn’t background noise. It’s a set of rule changes that affect prosecution strategy, portfolio valuation, dual filing decisions, and the strength of invalidation proceedings. This article covers the five most consequential changes and what each one means in practice.
What CNIPA Order No. 84 Actually Is — and Why It Matters
China’s Patent Examination Guidelines are the operational rulebook for CNIPA examiners — the document that governs how every Chinese patent application is examined, how claims are assessed for novelty and inventiveness, how amendments are handled, and how invalidation proceedings are conducted. When CNIPA revises these guidelines, it changes how the largest patent office in the world processes the largest volume of patent applications in the world.
To put the volume in context: CNIPA received over 1.6 million patent applications in 2024. That number has grown every year for the past decade. China is not just the largest patent filing jurisdiction by volume — it is increasingly significant by quality. Granted Chinese patents since 2018 reflect materially higher examination standards and growing enforceability, both domestically and internationally through PCT filings. Order No. 84 doesn’t change the volume. It raises the standard.
The effective date of January 1, 2026 means these rules are live now. Applications already in examination, pending dual filings, and ongoing invalidation proceedings are all affected. There is no grace period.
Change 1: New AI Invention Ethics Rules
This is the change that has received the most attention — and it’s worth understanding precisely what it does and doesn’t cover.
The revised guidelines introduce ethical screening for AI and algorithm-related patent applications. An application whose data collection, tag management, or decision-making contains content that violates laws, social ethics, or harms public interest will be rejected. This isn’t a soft guidance suggestion — it’s a formal examination criterion.
CNIPA’s own guidance provides a specific example: an emergency decision-making model for autonomous vehicles that uses passengers’ gender and age to determine collision priorities was cited as ineligible. The selection of protected objects based on gender and age goes against equal rights — and the application fails the ethical standard regardless of its technical merit.
Three things to understand about the ethics review:
- It applies to the claim as a whole, not just specific features. You can’t isolate the ethically problematic component and argue it’s not claimed. The examiner reviews the claimed technical solution in its entirety.
- It applies regardless of whether the application is commercial or research-oriented. The standard is objective — does the claimed solution violate law, social ethics, or harm public interest? Intent is not a factor.
- It affects how AI and algorithm applications need to be drafted. Applications must demonstrate a technical contribution that is ethically neutral and socially positive. The ethics review is now part of the prosecution process from filing.
For companies with AI patent pipelines that include data-driven decision systems, autonomous operation models, or algorithmic prioritisation mechanisms, every pending and future application needs to be assessed through this lens before filing in China.
Before: An autonomous vehicle emergency decision model using passenger demographic data to prioritise collision outcomes. Technical contribution clear. Ethically problematic under the new standard. Rejected.
After: The same core technical solution restructured to remove demographic-based prioritisation. Technical contribution preserved. Ethically neutral. Passes the new examination criterion.
Change 2: The Dual Filing Ban
This is the change with the most immediate operational impact for companies managing active Chinese patent portfolios.
Under the previous system, companies could file both an invention patent (subject to full substantive examination, typically taking 2–3 years to grant) and a utility model (granted without substantive examination, typically within 6– 12 months) for the same invention on the same day. This gave companies faster protection through the utility model while waiting for the longer invention patent process to complete.
Under Order No. 84: when an invention patent application is ready to be granted, the applicant must now abandon the utility model for the same invention. The previous option — amending the utility model claims to create a sufficient distinction from the invention patent — has been eliminated. The dual filing ban doesn’t eliminate utility models. It eliminates the simultaneous maintenance of both rights for the same invention.
What this means in practice:
- For pending dual filings: if you have existing applications where both an invention patent and utility model are pending for the same invention, the decision about which right to preserve must now be made before the invention patent reaches the grant stage. Waiting until the examiner’s notice of allowance is not the time to be reviewing this.
- For future filings: the dual filing strategy as a risk hedge is no longer available. Companies need to make an upfront decision: file an invention patent for stronger, longer-lived protection, or file a utility model for faster, lower-bar protection. Not both.
- For portfolio valuation: Chinese portfolios that carry both utility models and invention patents for the same inventions will need to be reviewed and the overlapping pairs resolved. Maintaining duplicated protection that will need to be collapsed is an unnecessary cost.
Change 3: The ‘Substantially Same Evidence’ Invalidation Standard
If you’ve been involved in Chinese patent litigation — on either side of a validity challenge — you’ll understand why this change matters.
Chinese patent invalidation has historically been characterised by serial challenge campaigns — competitors repeatedly challenging the same patent with slightly different arguments, keeping the patent locked in CNIPA proceedings and its enforceability uncertain for years. The previous rule barred challenges based on ‘the same reasons and evidence’ — interpreted so narrowly that minimally modified arguments could restart the process entirely.
Order No. 84 expands the prohibition to bar challenges based on ‘the same or substantially the same reasons and evidence.’ The word ‘substantially’ is the operative change — it closes the loophole that allowed serial challengers to restart proceedings with minor argument variations.
The only exception: reasons or evidence that were not considered in the prior proceeding due to time limits or procedural constraints. Everything else is barred. This means the first invalidation filing is now the most strategically important document in a Chinese patent challenge. There may not be a second attempt.
Order No. 84 also addresses the straw-man problem directly. Invalidation requests that do not reflect the true intention of the requester will be rejected — targeting the practice of competitors using unrelated third parties to file challenges on their behalf. Patent agencies are now legally required to verify applicant identity, and agencies filing requests in their own names face penalties. For more context on how CNIPA invalidation proceedings sit within the broader global invalidation landscape, TTC’s analysis of the global shift in patent invalidation covers how China’s approach compares to PTAB and EPO proceedings.
“The 2026 CNIPA reform sends a clear message to serial challengers: front-load your strongest arguments in the first filing, because the substantially same evidence standard means there may not be a second chance. For patent holders, it’s the strongest procedural protection against repeat invalidity attacks that Chinese patent law has ever provided.”
Changes 4 and 5: Inventor Identity and AI Inventiveness Assessment
These two changes are closely related — and both have direct implications for companies using generative AI and LLMs in their R&D workflows.
Change 4: Natural Persons Only — No AI Inventors
Order No. 84 explicitly requires that all inventors be natural persons — banning AI systems, entities, or groups from being listed as inventors. Identity information (nationality and, for Chinese nationals, ID card numbers) must be disclosed for all named inventors. Patent agencies are required to verify applicant identity.
The practical implication for international companies is straightforward but important: any pending Chinese application, and any future filing in China, must list only natural persons as inventors with accurate, verifiable identity information. Applications listing AI systems as inventors will be rejected. For companies using AI tools extensively in R&D, the human contribution to each invention must be clearly documented and reflected in inventorship decisions before the Chinese application is filed.
Change 5: Inventiveness Assessment for AI and Algorithm Applications
The revised guidelines clarify that inventiveness for AI and algorithm applications must be assessed for the claimed technical solution as a whole — not just the algorithmic features. Features that don’t contribute to solving a technical problem are not relevant to inventiveness.
This addresses a specific prosecution strategy that had become common: loading AI patent applications with extensive technical features to inflate the apparent inventiveness of what was essentially an algorithmic contribution. Under Order No. 84, examiners are explicitly instructed to assess whether each claimed feature actually contributes to the technical solution. Volume of technical features no longer substitutes for genuine inventive step.
For companies prosecuting AI and software patents in China: claims should be structured so that each feature contributes to a specific technical problem and its solution. The prosecution strategy of adding technical complexity to shore up inventiveness is now explicitly disfavoured by CNIPA.
How Our Portfolio Analysis Service Helps Navigate the CNIPA Changes
Order No. 84 creates five specific review tasks for companies with Chinese patent portfolios — and our patent portfolio analysis service is structured to address each one.
- Dual filing review. We identify every pending application pair where an invention patent and utility model are in prosecution for the same invention, assess the stage of each, and recommend which right to preserve and on what timeline.
- AI ethics assessment for pending applications. For companies with AI and algorithm-related applications pending at CNIPA, we review pending claims against the new ethical screening criteria — identifying applications that need restructuring before examination reaches the relevant stage.
- Inventor identity audit. We review pending and recently granted Chinese applications for inventor identity completeness and accuracy under the new Order No. 84 requirements.
- Invalidation exposure pre-screening. For key Chinese patents that are commercially active and potentially subject to challenge, we provide validity pre-screening under the new substantially same evidence standard — identifying the most likely prior art before a challenge is filed.
- AI claim structure review. For companies with AI patent pipelines, we review pending claim structures against the new inventiveness assessment standard and recommend prosecution adjustments.
For companies planning to enter or expand in China for the first time, our guide to worldwide IP defence and international patent strategy covers the broader framework for building a Chinese filing strategy within a global portfolio context.
Your Chinese patent portfolio is operating under new rules from January 2026. Our portfolio analysis service maps the impact of CNIPA Order No. 84 on every key asset — pending applications, active grants, and your invalidation exposure. → Contact Us
Conclusion: The Takeaway
The January 2026 CNIPA guidelines are not a minor procedural update. They change how AI inventions are examined, how dual filing works, how invalidation proceedings can be sequenced, how inventors are identified, and how inventiveness is assessed for algorithm-based claims.
For international companies with Chinese portfolios, the immediate tasks are clear: review pending dual filings before invention patents reach the grant stage, assess AI-related applications against the new ethics criteria, audit inventor identity disclosures, and front-load prior art in any invalidation filings. These aren’t strategic considerations for the next planning cycle — the rules are already in effect.
China is the world’s largest patent filing jurisdiction. The companies that adapt their prosecution and portfolio strategy to Order No. 84 quickly are the ones whose Chinese patent portfolios will hold up under examination, enforcement, and challenge. The ones that don’t are building on rules that no longer exist.
